Practical Lessons and Insights from Seasoned Drug Hunters
Other articles you may be interested in
What is a Biologic Drug Anyway?
or, How I Learned to Stop Worrying and Love My Own Definition. Recently I posted on “biologic drugs” which were approved in 2019 . All was well in my little scientific universe, until I received this in an email: “You recently reported "14 novel biologic drugs," referring to 'novel' biopharmaceuticals approved CDER. But, … You also include [...]
Not Your Grandparents’ Drugs: How Approved Drugs Have Evolved Since the 70’s
We recently explored how the lipophilicity (logP) of drugs has changed over time and found that, on average, drugs have become more lipophilic through the decades, primarily attributable to the industry’s move away from natural products. Despite this shift, it is clear from a broad qualitative comparison of structures from past decades to [...]
It Takes a Village
New drugs are discovered by teams, not individuals. "Drug discovery is a complex undertaking, and I enjoy the collaboration with many people from different disciplines and expertise areas that it takes to solve this impossible puzzle," says reviewer Joachim Rudolph . Drug Hunter also takes a community to build, and we [...]
Drug Hunter Letters #3 - September 2022
This edition of Drug Hunter Letters highlights recent insightful communications from Drug Hunter readers, including: Simon Bury on the History of GSK’s Recently Acquired $1.9B JAK Inhibitor Callie Bryan and Bryan McKibben on Insulin Receptor Partial Agonists and Recent Oncology Highlights Jesse Keicher on CXCR1/2 Antagonists in Treating [...]
"Don't Work on Things That Don't Work"
At the time of this writing Kim Huard was one of Genentech’s Senior Scientists, and has spent a decade looking for new medicines. She spent eight years at Pfizer at the Groton and Cambridge sites before joining us in California. She's currently a Director in the Discovery Chemistry department leading teams of scientists in pursuit of new [...]
